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time consuming and labor intensive by traditional bacteriological methods.
From our previous report [Yi et al., (1998) Use of Fluorescein Labelled
Antibody and Fluorescence Activated Cell Sorter for Rapid Identification of
Mycobacterium species. Biochem. Biophy. Res. Commu. 250: 403e408.], we
have used Flow Cytometry for rapid identification of Mycobacterium species.
However, identification of Mycobacterium to the species level can be
achieved only depending on the availability of species-specific antibody.
In this presentation, a rapid method involving intact cell mass spectrometry
(ICMS) is presented that shows promise for identification, typing and discrim-
ination of NTM species. In ICMS, cells from a bacterial colony are emulsified in a
chemical matrix, added to a sample probe, dried and analysed by matrix-
assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-
TOF-MS). This technique analyses proteins from intact and disrupted bacteria
yielding spectra consisting of 16 peaks from 5000 to 17500, which represent the
mass:charge (m:z) ratios. Each peak corresponds to a molecular fragment
released from the cell surface during laser desorption. Specimens can be
prepared in a few seconds from plate cultures and a spectrum can be obtained
within 10 min. Our results show that MALDI-TOF-MS is applicable for rapid
identification and differentiation of NTM, and thus shows its potential for
clinical NTM identification, or for epidemiological studies.SP 14-3
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Clinical microbiology is a discipline that focuses primarily on the rapidly
characterizing pathogen samples to direct the management of infected
individual patients and to monitor the epidemiology of infectious disease. A
brief overview of current practice through reviewing some recent articles
has focused on three essential tasks, and also outlined the potential of
sequencing technology to deliver the following key diagnostic information in
the clinical microbiology laboratory: identification of species, antimicrobial
resistance and presence of virulence determinants and strain typing to
detect outbreaks and support surveillance.
DNA sequencing is a powerful method to unravel genetic diversity of
microorganisms. Invention of next generation sequencing (NGS) which
enables massive and cost-effective DNA sequencing has revolutionized the
modern microbiology. Whole-genome sequencing yields all of the available
DNA information content on isolates in a single rapid step. The result
contains all of the data that are currently used for diagnostic and typing
needs, even though how to interpret the data is unknown sometimes.
However, the genome also includes vast amount of additional data that are
currently unavailable for routine processing, thus opening the prospect for
large-scale research into pathogen genotype-phenotype associations from
routinely collected data. High-throughput methods using NGS are evolutio-
nising bacterial genomics, providing sufficient resolution potentially to
determine which cases within temporo-spatial clusters are likely to be
related. With the advent of rapid sequencers, sources of outbreaks have
been identified in clinically relevant timescales, demonstrating the potential
of NGS to transform infection control practice. Genome sequences poten-
tially provide a high-resolution, accurate and reproducible means for
relating organisms. Sequencing can also rapidly provide a clear understand-
ing of the origins of a local outbreak. Examples of the effectiveness of whole
genome analysis for unraveling the origins and dispersal of pathogens at
regional and global scales have recently been published. Herein, the
recently published aritcles will be reviewed at this time.
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Tuberculosis (TB) is caused by Mycobacterium tuberculosis complex (MTBC);
the disease is an important public health problem worldwide. Although the
global incidence of TB is decreasing, multidrug-resistant TB (MDR-TB) and
extensively drug-resistant TB (XDR-TB) are increasing. The conventional
method of drug susceptibility testing of MTBC takes 3 weeks. The aim of this
study was to detect point mutations in genes of MTBC conferring resistance
to the first and second line drugs [rifampin (RMP), isoniazid (INH), ethambutol
(EMB), streptomycin (SM), ofloxacin (OFX), kanamycin (KA), capreomycin
(CAP), and amikacin (AM)] in positive cultures of Mycobacterial Growth Indica-
tor Tube (MGIT). The method consisted of multiplex PCR (13 pairs of primers)
amplification of the relevant genes, followed by hybridization of the digoxige-
nin-labeled PCR products to probes immobilized on a nylon array. A total of
1426 positive MGIT cultures were analyzed. The sensitivities of the array
(based on patient number) were 91.7% (RMP), 88.9% (INH), 100% (EMB),
82.4% (SM), 100% (OFX), 100% (KA), 50.0% (CAP) and 100% (AM), respectively;
while the specificities were respectively 98.9% (RMP), 99.4% (INH), 99.5%
(EMB), 100% (SM), 100% (OFX), 100% (KA), 99.0% (CAP) and 99.5% (AM). The pos-
itive predictive values were 91.7% (RMP), 97.0% (INH), 92.9% (EMB), 100% (SM),
100% (OFX), 100% (KA), 33.3% (CAP) and 66.7% (AM), respectively; while the
negative predictive values were respectively 98.7% (RMP), 97.7% (INH), 100%
(EMB), 98.4% (SM), 100% (OFX), 100% (KA), 99.5% (CAP) and 100% (AM). In
conclusion, the array can effectively detect gene mutations causing drug
resistance to some important first and second line anti-TB antibiotics in posi-
tive MGIT cultures, except CAP, in a working day.SP 15-2
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Syphilis remains a major public health problem in many low-income
countries that have limited capacity for laboratory testing, which tradition-
ally relies on use of a non-treponemal test for screening, followed by
confirmation of reactive sera using a treponemal test. However, traditional
tests are usually limited by needs of serum or plasma preparation,
equipment, skilled technician, and electricity. The development of rapid
diagnostics for syphilis (rapid syphilis tests) provides an opportunity to scale
up syphilis screening in many settings where traditional testing is unavai-
lable. Several formats of rapid syphilis tests including single rapid trepo-
nemal test, combined treponemal and non-treponemal test, and dual HIV-1/
2 and treponemal test are commercially available and more are in the
pipeline. Some of these tests have been independently evaluated for their
performance in terms of sensitivity and specificity at qualified laboratories
in multiple sites and showed high performance and favorable operational
characteristics. Based on evidence from evaluation studies, many countries
have changed their policies to adopt syphilis testing with rapid syphilis test
into their screening programmes to improve intervention of syphilis among
